Patent ID: 8314148

Claim:
A method of treating a disorder or a disease selected from the group consisting of Alport syndrome, asthma, rhinitis, chronic obstructive pulmonary diseases (COPD), arthritis, atherosclerosis and restenosis, diseases involving tissue destruction, loosening of hip joint replacements, periodontal disease, fibrotic disease, infarction and heart disease, liver and renal fibrosis, endometriosis, diseases related to the weakening of the extracellular matrix, heart failure and aortic aneurysms in a subject mediated by MMP-9, and/or MMP-12 and/or MMP-13, comprising: administering to the subject a therapeutically effective amount of a compound of formula (I) wherein R 1 is cyano, (C 1 -C 7 )alkyl, amino, R 4 —O—, (C 1 -C 7 )alkyl-NHC(O)—, R 5 —C(O)NH—, R 6 C(O)—, or R 9 —C(O)—O—or R 10 —O—C(O)—, wherein R 4 , R 6 , R 9 and R 10 are independently hydrogen, (C 1 -C 7 )alkyl, mono- or di-(C 1 -C 7 )alkylamino or aryl each of which is optionally substituted by one to five substituents selected from the group consisting of (C 1 -C 7 ) alkyl, halo, hydroxyl, (C 1 -C 7 ) alkoxy and aryl; R 5 is hydrogen, (C 1 -C 7 )alkyl, (R 7 )(R 8 )N—, or (C 1 -C 7 ) alkoxy; R 7 and R 8 are independently hydrogen, (C 1 -C 7 )alkyl, or aryl-(C 1 -C 7 )alkyl; R2 is hydrogen, or (C 1 -C7)alkyl which is optionally substituted by one to three substituents selected from the group consisting of (C 1 -C 7 )alkyl, hydroxy, aryl, heterocyclyl, heteroaryl, (C 1 -C 7 )alkyl-O—C(O)—, di-(C 1 -C 7 )alkylamino-C(O)—, wherein each of aryl, heterocyclyl, and heteroaryl is further optionally substituted by (C 1 -C 7 )alkyl; and R 3 is (C 1 -C 7 )alkyl, or cycloalkyl; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers.